The global oncology blockbuster drugs market is significantly influenced by the increasing global prevalence of cancer. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Breast cancer remains the most common type of cancer, with an estimated 2.3 million new cases reported globally in 2020, followed by lung cancer, which accounted for 2.2 million new cases. The rising incidence of various cancer types, such as colorectal, prostate, and liver cancer, is driving the demand for effective oncology therapies. Additionally, advancements in immunotherapy and targeted therapies are transforming cancer treatment paradigms, increasing the use of monoclonal antibodies and checkpoint inhibitors. For instance, immunotherapies such as pembrolizumab (Keytruda) and nivolumab (Opdivo) have shown substantial clinical benefits in the treatment of lung cancer and melanoma. With the growing global cancer burden and the increasing availability of advanced treatments, the oncology blockbuster drugs market is poised for continued growth, offering promising therapeutic options for patients worldwide.
